The relevance of targeting this cytokine in patients with diabetic nephropathy is further stressed by an ongoing trial testing an anti-IL-6 biological, i.e. ziltivekimab, in patients with chronic kidney disease and with high hs-CRP levels, with the majority of patients having diabetic kidney disease [61]. This evidence concerns the gene IL6 and chronic kidney disease.